selectION, Inc. to Present Update on Clinical Progress at th

Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patientsPipeline molecule to treat T cell mediated autoimmune diseases

Related Keywords

San Diego , California , United States , Martinsried , Bayern , Germany , Munich , Steve Zaniboni , Ludger Wess Ines Regina Buth , Lion Inc , Golden Gate , Global Source , Ludger Wess , Business ,